• Loading stock data…

rumor

Could This Biotech Stock Get Bought For $5.5 Billion? Either Way I’m Buying It

On Friday May 24th, 2019 Novartis (NYSE: NVS) gained FDA approval of its gene therapy product " Zolgensma® " for spinal muscular atrophy (SMA), originally purchased from AveXis in 2018 for $8.7 … [Read more...] about Could This Biotech Stock Get Bought For $5.5 Billion? Either Way I’m Buying It